Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - efmody
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mpd70366d9de20b85af1c498f11302a348
identifier: http://ema.europa.eu/identifier
/EU/1/21/1549/001 (50 capsules)
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Efmody 5 mg modified-release hard capsules
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-d70366d9de20b85af1c498f11302a348
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/21/1549/001 (50 capsules)
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - efmody
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Medicine contains the active substance hydrocortisone. Hydrocortisone belongs to a group of medicines known as corticosteroids.
Hydrocortisone is a copy of the hormone cortisol. Cortisol is made by the adrenal glands in the body.
Efmody is used when the adrenal gland are not making enough cortisol due to an inherited condition called congenital adrenal hyperplasia. It is for use in adults and adolescents from 12 years of age.
Do not take Efmody
Warnings and precautions Talk to your doctor or pharmacist before taking Efmody if the following apply:
Adrenal crisis
Fertility
Other
You should not stop taking Efmody without checking with your doctor as this could make you seriously unwell very quickly.
As Efmody is replacing the normal hormone your body lacks, side effects are less likely, however:
Too much Efmody can affect your bones so your doctor will monitor the dose closely.
Some patients taking hydrocortisone Efmody became anxious, depressed or confused.Tell your doctor if you develop any unusual behaviour or feel suicidal after starting medication (see section 4).
In rare cases allergy to hydrocortisone can occur. People who already have allergies to other medicines may be more likely to develop allergy to hydrocortisone.Tell your doctor straight away if you have any reaction like swelling or shortness of breath after being given Efmody (see section 4).
Hydrocortisone may cause diabetes. If you have symptoms of excessive thirst or need to pass urine excessively tell your doctor straight away.
Treatment with steroids can lead to low blood potassium. Your doctor will monitor your potassium levels to check for any changes.
Hydrocortisone can reduce growth in children.Your doctor will monitor your growth while you are on Efmody.
Children with congenital adrenal hyperplasia taking hydrocortisone might show signs of sexual development or puberty earlier than usually expected.Your doctor will monitor your development while you are on Efmody.
Contact your doctor if you have blurred vision or other visual disturbances.
Other medicines and Efmody Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Some medicines can affect the way that Efmody works and may mean that your doctor needs to alter your dose of Efmody.
Your doctor may need to increase your dose of Efmody if you take certain medicines, including:
Your doctor may need to decrease your dose of Efmody if you take certain medicines including:
Efmody with food and drink Some food and drink may affect the way Efmody works and may need your doctor to decrease your dose. These include:
Pregnancy, breast-feeding and fertility Hydrocortisone is known to cross the placenta in pregnancy and is present in breast milk, however there is no evidence this causes any harm to the infant. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
If you are a woman who has not gone through menopause your periods might return or become more regular. The restored fertility may lead to unexpected pregnancy even before the reoccurrence of menstrual bleeding. See also section Warnings and Precautions regarding fertility in both men and women.
Driving and using machines Efmody has minor influence on the ability to drive and use machines. Untreated adrenal insufficiency may affect the ability to drive and use machines. Tell your doctor immediately if you feel tired or dizzy when taking Efmody.
Always use this medicine exactly as your doctor, nurse or pharmacist has told you. Check with them if you are not sure.
Your doctor will decide on the right starting dose of Efmody and then adjust the dose as needed. During illnesses, around the time of surgery and during times of serious stress, your doctor may ask you to take another corticosteroid medicine instead of, or as well as, Efmody.
The initial daily dose may be divided into 2 doses with two thirds to three quarters of your daily dose in the evening at bedtime and the rest given in the morning.
The morning dose of hydrocortisone modified-release hard capsules should be taken on an empty stomach at least 1 hour before a meal and the evening dose taken at bedtime at least 2 hours after the last meal of the day.
Use in Children No information on the safety and efficacy of Efmody in children under 12 years is available. Other hydrocortisone containing medicines are available for children under 12 years.
How to take this medicine Swallow the capsules with water .
Do not chew the capsules as it could change the release of the medicine.
If you take more Efmody than you should If you take more Efmody than you should, contact your doctor or pharmacist for further advice as soon as possible.
If you forget to take Efmody If you forget to take a dose, take the dose as soon as possible.
If you stop taking Efmody Do not stop taking Efmody without asking your doctor first. Stopping the medicine suddenly could quickly lead to an adrenal crisis.
If you become unwell Tell your doctor or pharmacist if you become ill, suffer severe stress, get injured or are about to have surgery because your doctor may advise that you another corticosteroid medicine instead of, or as well as, Efmody (see section 2).
If you take too much Efmody Poisoning or death are rare with too much Efmody, but you should inform your doctor immediately. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you have any reaction like swelling or shortness of breath after taking Efmody, get medical help straight away and tell your doctor as soon as possible as these can be signs of an severe allergic reaction (anaphylactoid reactions) (see section 2).
Adrenal crisis and adrenal insufficiency symptoms have been reported commonly (may affect up to 1 in 10 people). If you get less hydrocortisone than you need you may become seriously unwell. If you feel unwell and particularly if you start vomiting you must tell your doctor straight away as you may need extra hydrocortisone or an injection of hydrocortisone.
Tell your doctor about any of the following side effects as soon as possible:
Very Common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Feeling sick (nausea)
Belly (abdominal) pain
Loss of energy or weakness
Increased or decreased appetite and weight gain or loss
Muscle pains and weakness
Joint pains
Headache
Dizziness
Pain or tingling in the thumb or fingers (carpal tunnel syndrome)
Tingling
Insomnia, sleep difficulties or unusual dreams
Depressed mood
Acne
Hair growth
Changes in blood tests of kidney and glucose
Long-term treatment with hydrocortisone may reduce bone density. Your doctor will monitor your bones (see section 2).
People who require treatment with steroids may have a higher risk of heart disease. Your doctor will monitor you for this.
Long term treatment with hydrocortisone can affect growth in children and young people. Your doctor will monitor your growth in young people. Some children with congenital adrenal hyperplasia treated with hydrocortisone can have an earlier puberty than expected. Your doctor will monitor your development (see section 2).
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.
You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the bottle and carton after EXP.
The expiry date refers to the last day of that month.
This medicine does not have any special temperature storage requirements.
Store in the original package.
Keep the bottle tightly closed in order to protect from moisture.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Efmody contains
Capsule
The capsule is made from gelatin.
Efmody 5 mg modified-release hard capsules (white/blue) Titanium dioxide (E171) and indigotine (E132)
Efmody 10 mg modified-release hard capsules (white/green) Titanium dioxide (E171), indigotine (E132) and yellow iron oxide (E172)
Efmody 20 mg modified-release hard capsules (white/orange) Titanium dioxide (E171), yellow iron oxide (E172) and red iron oxide (E172)
Printing ink
The printing ink on the capsules contains shellac, black iron oxide (E172), propylene glycol and potassium hydroxide
What Efmody looks like and contents of the pack
Efmody 5 mg modified-release hard capsules A capsule (approx.19 mm long) with an opaque blue cap and opaque white body printed with CHC 5mg containing white to off white granules.
Efmody 10 mg modified-release hard capsules A capsule (approx.19 mm long) with an opaque green cap and opaque white body printed with CHC 10mg containing white to off white granules.
Efmody 20 mg modified-release hard capsules A capsule (approx. 22 mm long) with an opaque orange cap and opaque white body printed with CHC 20mg containing white to off white granules.
Efmody comes in a high density polyethylene bottles with child resistant, tamper-evident polypropylene screw cap with integrated desiccant. Each bottle contains 50 modified-release hard capsules.
Pack size:
Carton containing 1 bottle of 50 modified-release hard capsules.
Carton containing 2 bottles of 50 modified-release hard capsules (100 capsules).
Not all pack sizes may be marketed.
Marketing Authorisation Holder Diurnal Europe B.V. Van Heuven Goedhartlaan 935 A 1181LD Amstelveen
The Netherlands
Manufacturer Delpharm Lille SAS
Parc d'Activit s Roubaix-Est
22 rue de Toufflers CS 50Lys Lez Lannoy, 59 France
Wasdell Europe Limited IDA Dundalk Science and Technology Park Mullagharlin Dundalk
Co. Louth, A91 DET0 Ireland
This leaflet was last revised in
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-d70366d9de20b85af1c498f11302a348
Resource Composition:
Generated Narrative: Composition composition-en-d70366d9de20b85af1c498f11302a348
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/21/1549/001 (50 capsules)status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - efmody
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mpd70366d9de20b85af1c498f11302a348
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mpd70366d9de20b85af1c498f11302a348
identifier:
http://ema.europa.eu/identifier
/EU/1/21/1549/001 (50 capsules)type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Efmody 5 mg modified-release hard capsules
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en